Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
The latest update is out from Advanced Medical Solutions ( (GB:AMS) ).
Advanced Medical Solutions Group plc has announced a delay in its Annual General Meeting (AGM) to 30 June 2025 due to unforeseen changes within its audit team at Deloitte LLP. Consequently, the record date for the proposed final dividend of 1.83p per share has been moved to 20 June 2025, with the dividend payment scheduled for 17 July 2025, pending shareholder approval at the AGM. This adjustment reflects the company’s commitment to maintaining transparency and adapting to operational changes, which may impact shareholder expectations and financial planning.
The most recent analyst rating on (GB:AMS) stock is a Buy with a £2.45 price target. To see the full list of analyst forecasts on Advanced Medical Solutions stock, see the GB:AMS Stock Forecast page.
Spark’s Take on GB:AMS Stock
According to Spark, TipRanks’ AI Analyst, GB:AMS is a Neutral.
Advanced Medical Solutions shows strong revenue growth and a solid capital structure, but faces challenges with declining profit margins and operational efficiency. The stock’s technical indicators suggest a bearish trend, while valuation metrics indicate potential overvaluation. Positive corporate events, including strategic acquisitions and board enhancements, support future growth prospects. Overall, the stock presents a mix of strengths and risks, resulting in a moderate score.
To see Spark’s full report on GB:AMS stock, click here.
More about Advanced Medical Solutions
Advanced Medical Solutions Group plc (AMS) is a leading independent developer and manufacturer of innovative tissue-healing technologies, focusing on delivering quality outcomes for patients and value for payers. The company offers a wide range of surgical products, including tissue adhesives, sutures, haemostats, and internal fixation devices, marketed under various brands such as LiquiBand®, RESORBA®, and Seal-G®. AMS also provides wound care dressings and has expanded its portfolio through multiple acquisitions since 2019. With a global presence, AMS operates R&D hubs in several countries and employs over 1,600 people.
Average Trading Volume: 1,088,558
Technical Sentiment Signal: Sell
Current Market Cap: £420.2M
For a thorough assessment of AMS stock, go to TipRanks’ Stock Analysis page.